New drug cocktail aims to wipe out bladder tumors before surgery
NCT ID NCT06133517
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of three drugs—sacituzumab govitecan, zimberelimab, and domvanalimab—given before and after surgery for muscle-invasive bladder cancer. The study includes 70 patients who cannot take standard cisplatin chemotherapy. The main goal is to see if the treatment can completely eliminate the tumor by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan (Trodelvy), zimberelimab, and domvanalimab
What this could lead to
If this works, it could offer a new treatment option for people with muscle-invasive bladder cancer who cannot have standard chemotherapy, potentially eliminating the tumor before surgery.
What could go wrong
This is a small, early-phase trial with only 70 participants and no comparison group. The combination may cause significant side effects, and it is not yet known if it improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clinico Universitario de Valladolid
Valladolid, Valladolid, Spain
-
Hospital Clínico San Carlos
Madrid, Madrid, Spain
-
Hospital Duran i Reynals (ICO L´Hospitalet)
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
-
Hospital Universitario de Navarra
Pamplona, Navarre, Spain
-
Hospital Virgen de la Salud
Toledo, Toledo, Spain